Page 48 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $31.50
52wk Low $0.34 Tharimmune, Inc. THAR $0.37
1200 Route 22 East
Bridgewater, NJ 08807

(USD - in millions) www.tharimmune.com
Market Cap 4.5
Enterprise (6.4)
Basic Shares Out. 11.79 COMPANY OVERVIEW
Float 11.57
Institutional Holdings 1.16% Detailed Analysis:Channelchek.com
Short Interest 0.08
Avg. 90-Day Volume 0.52 Tharimmune, Inc. is a clinical-stage biotechnology company developing
a portfolio of therapeutic candidates for inflammation and immunology.
The Company's lead clinical-stage asset, TH104 is known to suppress
chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare
EPS Data and orphan liver disease with no known cure. The Company's early-
stage immunology pipeline includes novel multi-specific antibodies
2021 2022 2023 targeting unique epitopes with novel mechanisms of action against well-
CQ1 N/A N/A N/A known, validated targets in multiple solid tumors, including PD-1, HER2
CQ2 N/A N/A N/A and HER3. Tharimmune has a license agreement with OmniAb, Inc. to
access the company's antibody discovery technology platform against
CQ3 N/A N/A N/A these and other specified targets.
CQ4 N/A N/A N/A
CY N/A N/A N/A Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.78
ROE (ttm) -127.01
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
1200 Route 22 Bridgewater NJ 08807

Key Executives
CEO: Milby, Randy
CFO: Hess, Thomas
COO: Appajosyula, Sireesh
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures